CLICK BELOW TO DOWNLOAD A PDF OF THE MONOGRAPH.
Click on the thumbnail to open and print the PDF file, or, to download and save the file to your desktop, please "right click" on the thumbnail and select "Save Target As..."

Featuring
John Betteridge, MD, PhD
London, England

Ralph A. DeFronzo, MD
San Antonio, Texas

Ele Ferrannini, MD
Pisa, Italy

Michael Nauck, MD, PhD
Bad Lauterberg, Germany

 

An in-depth CME/CE Monograph based on the symposium given at the American Diabetes Association's 67th Scientific Sessions, Sunday, June 24, 2007

Release Date: February 2008
Expiration Date:
February 28, 2009

To reserve your FREE copy of the monograph, call 800-260-4378, extension 315, or CLICK HERE to download the simple request form. You may also download a PDF of the monograph by clicking the thumbnail on the left side of this screen.


Since oral antidiabetic agents were first used in the 1950s, new classes of agents and refinements within the classes have provided a wider array of treatment options for diabetes. Despite treatment advances, diabetes continues to be poorly controlled for many patients. A recent flurry of research has advanced our understanding of diabetes pathogenesis and highlighted the novel approaches that may better limit glucose toxicity and potentially minimize the long-term outcomes of the disease. Advances in the understanding of diabetes pathogenesis and new ways of managing the disease from a mechanistic point of view will be reviewed.


The target audience for this monograph is diabetologists and other clinicians including physicians, nurses, pharmacists, dietitians, psychologists, and podiatrists with expertise in diabetes.


Upon completion of this program, participants should be able to:
• Explain the long-term consequences of poor glucose control in type 2 diabetes mellitus (DM)
• Describe beta-cell failure and its effect on the progression of type 2 DM
• Identify new or emerging pharmacotherapeutic options and how their novel mechanisms may be useful in treating type 2 DM


The Center for Health Care Education, LLC (CHCE), is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.


CHCE designates this educational activity for a maximum of 2.0 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

This continuing nursing education activity is approved by CHCE for 2.4 Contact Hours (CHs). CHCE is an Approved Provider of continuing nursing education by the North Carolina Nurses Association, an accredited approver by the American Nurses Credentialing Center's Commission on Accreditation.

To receive credit, participants must read through the monograph, complete the posttest and evaluation form, and submit to CHCE before the expiration date.